Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Innocenti

Showing results (91-100 of 186) with videos related to

Pageof 19
Sort By:
Human Mutation|November 5, 2013
Discovery and functional assessment of gene variants in the vascular endothelial growth factor pathwayLaia Paré-Brunet, Dylan Glubb, Patrick Evans, et al.
The Pharmacogenomics Journal|November 14, 2021
PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitorsJulia C F Quintanilha, Alessandro Racioppi, Jin Wang, et al.
Journal of Clinical Pharmacology|December 29, 2006
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicityRoshni P Ramchandani, Yaning Wang, Brian P Booth, et al.
Epigenetics|May 8, 2024
Evaluating the utility of <i>ZNF331</i> promoter methylation as a prognostic and predictive marker in stage III colon cancer: results from CALGB 89803 (Alliance)Elizabeth S Nakasone, Tyler J Zemla, Ming Yu, et al.
Cancer Chemotherapy and Pharmacology|February 20, 2007
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancerWei Peng Yong, Apurva A Desai, Federico Innocenti, et al.
Cancer Chemotherapy and Pharmacology|August 5, 2008
The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compoundsFederico Innocenti, Snezana Mirkov, Ramamoorthy Nagasubramanian, et al.
British Journal of Cancer|October 27, 2021
Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patientsSpinel Karas, Amy S Etheridge, Deborah A Nickerson, et al.
Clinical Pharmacology and Therapeutics|June 18, 2003
A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphineMichael B Sawyer, Federico Innocenti, Soma Das, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2004
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecanFederico Innocenti, Samir D Undevia, Lalitha Iyer, et al.
The Oncologist|June 3, 2024
Longitudinal patient-reported outcomes on genotype-guided irinotecan dosing: feasibility and clinical relevanceJonathan D Sorah, Allison M Deal, Sophia I Stein, et al.
Pageof 19

Showing results (91-100 of 186) with videos related to

Sort By:
Pageof 19
Human Mutation|November 5, 2013
Discovery and functional assessment of gene variants in the vascular endothelial growth factor pathwayLaia Paré-Brunet, Dylan Glubb, Patrick Evans, et al.
The Pharmacogenomics Journal|November 14, 2021
PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitorsJulia C F Quintanilha, Alessandro Racioppi, Jin Wang, et al.
Journal of Clinical Pharmacology|December 29, 2006
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicityRoshni P Ramchandani, Yaning Wang, Brian P Booth, et al.
Epigenetics|May 8, 2024
Evaluating the utility of <i>ZNF331</i> promoter methylation as a prognostic and predictive marker in stage III colon cancer: results from CALGB 89803 (Alliance)Elizabeth S Nakasone, Tyler J Zemla, Ming Yu, et al.
Cancer Chemotherapy and Pharmacology|February 20, 2007
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancerWei Peng Yong, Apurva A Desai, Federico Innocenti, et al.
Cancer Chemotherapy and Pharmacology|August 5, 2008
The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compoundsFederico Innocenti, Snezana Mirkov, Ramamoorthy Nagasubramanian, et al.
British Journal of Cancer|October 27, 2021
Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patientsSpinel Karas, Amy S Etheridge, Deborah A Nickerson, et al.
Clinical Pharmacology and Therapeutics|June 18, 2003
A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphineMichael B Sawyer, Federico Innocenti, Soma Das, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2004
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecanFederico Innocenti, Samir D Undevia, Lalitha Iyer, et al.
The Oncologist|June 3, 2024
Longitudinal patient-reported outcomes on genotype-guided irinotecan dosing: feasibility and clinical relevanceJonathan D Sorah, Allison M Deal, Sophia I Stein, et al.
Pageof 19